Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells

<table class="table-group" id="tab2"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left"> </td><td align="left">Risk factor degree</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left">Patient relating factors </td><td align="left">Pediatric age &gt;adult age</td></tr><tr><td align="left" rowspan="3">Treatment relating factors</td><td align="left">Radiotherapy &gt;chemotherapy</td></tr><tr><td align="left">Single dose &gt;fractioned dose TBI</td></tr><tr><td align="left">Intrathecal chemotherapy</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>TBI: “total body” irradiation. Symbol (&gt;) means more than.<br/></td></tr></table>

The Scientific World Journal

tab2

Table 2

Table 2: Endocrinopathies after Allogeneic and Autologous Transplantation of Hematopoietic Stem Cells 